Learn how K2B Therapeutics transitioned from the traditional incubator model to Labshares. The team was fully operational in less than 2 weeks, and now has the flexibility and support to continue growing.

Labshares appoints a Devon Lagasse as VP of Growth and promotes Emma Orfanos to Manager of Business Development, strengthening its leadership as the Greater Boston shared lab provider expands.

Abcuro reports preclincal data showing that KLRG1 antibody blockade produced anticancer responses in breast cancer, colon cancer, and melanoma models, supporting KLRG1 as a promising new immuno-oncology target.